Richard L. Lindstrom MD

Filings by Richard L. Lindstrom MD span 6 companies, the busiest being Ocular Therapeutix, Inc, Harrow, Inc. and LENSAR, Inc. Over a trading history stretching from 11 December 2007 to 20 February 2026, the count stands at 32 filings.

The open-market side counts 5 purchases for €842k alongside 6 sales for €905k. The totals exclude 1 filing filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 12 share grants and 6 option exercises. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €194k. Clusters matter here: 1 out of 4 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 24 February 2026, reports an open-market purchase of €392k in Ocular Therapeutix, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.